Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This 12-week, open-label, primary care study (NCT02195817) evaluated the efficacy and safety of nalmefene, taken as needed, to reduce alcohol consumption in adults with a diagnosis of alcohol dependence and drinking at least at high drinking risk levels (DRL, > 60 g/day for men, > 40 g/day for women).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur Addict Res

Title: European addiction research

Publisher: S. Karger AG

ISSN (Electronic): 1421-9891

ISSN (Print): 1022-6877

Publication date (Electronic): 2018

Volume: 24

Issue: 6

Affiliations

[1 ] Professeur Associé de Médecine Générale De l'Université De Bordeaux, Cabinet Medical, Bordeaux, France, philippe.castera@u-bordeaux.fr.

[2 ] NHS Lanarkshire Integrated Addiction Service, Coathill, Lanarkshire, United Kingdom.

[3 ] Gemeinschaftspraxis, Innere und Allgemeinmedizin, Wallerfing, Germany.

[4 ] Sardenya Primary Health Care Center, Biomedical Research Institute Sant PauPau (IIB-Sant Pau), Barcelona, Spain.

[5 ] H. Lundbeck A/S, Valby, Denmark.

[6 ] UCB Biopharma S.P.R.L, Brussels, Belgium.

Article

Publisher Item ID: 000494692

DOI: 10.1159/000494692

PubMed ID: 30485854

SO-VID: d0888f54-14ac-4dcb-8153-eab7cb25559d

History

Keywords: Alcohol dependence,Clinical trial,Nalmefene,Primary care

Data availability:

Keywords: Alcohol dependence, Clinical trial, Nalmefene, Primary care

Comments

Comment on this article

scite_

Cited by 5

See all cited by